PUBLIC COMPANY
saveBAUSCH
USupdated 2mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with statesSandoz agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices.stat · 5h ago
- STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with statesGlenmark Pharmaceuticals agreed to pay $29.6 million to settle price-fixing allegations in a long-running battle with dozens of states.stat · 19d ago
- Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectorPlus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or Ris-Rez, met its primary end…endpoints · 24d ago
- AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicineNewly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell…biopharma_dive · 1mo ago
- City banks nearly $100M for next-gen RNAi drugsCo-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.biopharma_dive · 1mo ago
comments(0)
5-min edit window · permanent after that